DoW Toxic Exposures Translational Research Award
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Offered by Defense Health Agency Contracting Activity - DHACA; awards $6.0M; applications due November 19, 2026.
Key Facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Award amount
- $6.0M
- Deadline
- November 19, 2026
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach...
Full requirements and application instructions: official listing.
Similar Open Grants
Department of Defense HIV/AIDS Prevention Program
Defense Health Agency Contracting Activity - DHACA
DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Defense Health Agency Contracting Activity - DHACA
DoW Spinal Cord Injury, Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Vision, Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Spinal Cord Injury, Clinical Translation Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Vision, Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
Easement Restoration and Stewardship
Natural Resources Conservation Service
FY27 Small Business Development Center State of Kansas Network Rebid
Small Business Administration
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health